RxDoctor Payments Data

Sara Hubbell

Acute Care · Cedar Rapids, IANPI 1356638266

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 35.1% of the total. Reporting peaked in 2021 at $299 and has fallen 61.6% since, to $115 in 2025.

$732in general payments, 2019–2025

Across 42 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$257
  • Pfizer$130
  • AstraZeneca$55
  • Novo Nordisk$55
  • Amgen$48
  • Biohaven Pharmaceuticals, Inc.$40
  • plus $146 from 7 others

What the payments were for

  • Food & beverage$71898%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$732 in reported general payments places this provider in the 65th percentile of 104 acute care providers in Iowa.

See all acute care providers in Iowa

Medicare billing

Part B allowed, 2024
$144,875
Medicare patients
221
Services billed
3,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide30$59,864
OzempicSemaglutide33$52,479
MounjaroTirzepatide38$49,439
EliquisApixaban34$34,000
XareltoRivaroxaban22$33,788
JardianceEmpagliflozin16$19,420
FarxigaDapagliflozin Propanediol13$19,111
RybelsusSemaglutide11$18,148
GemtesaVibegron14$7,251
Gabapentin193$3,137
Atorvastatin Calcium367$2,601
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$2,558
Levothyroxine Sodium362$2,247
Advair DiskusFluticasone Propion/Salmeterol13$1,825
Omeprazole212$1,648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$55$70,62744 claims
PfizerEliquis$130$34,00034 claims
Johnson & JohnsonXarelto$29$33,78822 claims
AstraZenecaFarxiga$55$19,11113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 104 acute care providers in Iowa.

Other acute care in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →